Borruat F X, Buechi E R, Piguet B, Fitting P, Zografos L, Herbort C P
Hôpital Ophtalmique Jules Gonin, Lausanne.
Klin Monbl Augenheilkd. 1991 May;198(5):358-60. doi: 10.1055/s-2008-1045980.
We compared the frequency of severe ocular complications secondary to Herpes Zoster Ophthalmicus (HZO) in 232 patients. They were divided into three groups: 1) patients without treatment (n = 164); 2) patients treated adequately (n = 48) with acyclovir (ACV; 5 x 800 mg/d orally and ophthalmic ointment 5 x /d for a minimum of 7 days, given within three days after skin eruption); and, 3) patients treated inadequately (n = 20) with ACV (only topical treatment, insufficient doses, interrupted treatment, delayed treatment). Patients with no treatment or with inadequate treatments showed the same frequency of severe ocular complications (21% (34/164) and 25% (5/20), respectively). In contrast, when adequate treatment of ACV was given complications occurred in only 4% (2/48) of cases. This study emphasizes the need for prompt (within three days after skin eruption) and adequate (5 x 800 mg/d for at least 7 days) treatment of ACV to prevent the severe complications of HZO.
我们比较了232例带状疱疹性眼炎(HZO)继发严重眼部并发症的发生率。他们被分为三组:1)未治疗的患者(n = 164);2)接受足量阿昔洛韦(ACV)治疗的患者(n = 48)(5×800mg/d口服及5次/d眼膏,至少7天,在皮疹出现后3天内给予);3)接受不足量阿昔洛韦治疗的患者(n = 20)(仅局部治疗、剂量不足、治疗中断、治疗延迟)。未治疗或治疗不足的患者严重眼部并发症发生率相同(分别为21%(34/164)和25%(5/20))。相比之下,给予足量阿昔洛韦治疗时,并发症仅发生在4%(2/48)的病例中。本研究强调需要在皮疹出现后3天内迅速给予足量(5×800mg/d至少7天)的阿昔洛韦治疗,以预防HZO的严重并发症。